Abiraterone acetate: a novel drug for castration-resistant prostate cancer

Ai Ping Zhou, Hong Fang, Chang Ling Li, Yan Sun

Research output: Contribution to journalArticlepeer-review


Castration-resistant prostate cancer (CRPC) is thought to be hormone driven. Inhibition of the androgen signal axis remains an important treatment strategy for CRPC. Abiraterone acetate, a selective potent inhibitor of CYP17, is able to further greatly decrease the serum testerone virtually to an undetectable level. Randomized phase III clinical trial has revealed that abiraterone acetate significantly increases PSA and tumor response rate, and prolongs time to disease progression and overall survival time. Abiraterone acetate has become a novel treatment option for CRPC patients. Abiraterone is well tolerated with a low incidence of grade 3 or 4 side effects.

Original languageEnglish
Pages (from-to)1998-2001
Number of pages4
JournalChinese Journal of New Drugs
Issue number17
StatePublished - Sep 15 2013


  • Abiraterone acetate
  • Castration-resistant prostate cancer
  • Pharmacokinetics
  • Pharmacology


Dive into the research topics of 'Abiraterone acetate: a novel drug for castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this